Payment overview · 2025
General Payments
$1,436.18
74 reported records · 21 companies
Healthcare provider profile · identity verified
Davey M Perrin, MD
Allopathic & Osteopathic Physicians|Family Medicine · ENNIS, TX · NPI 1518057439
Verified facts
What the public records show
CMS Open Payments records show Davey M Perrin, MD received $1,436.18 in general payments during 2025 across 74 reported records.
Corcept Therapeutics accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $242.57 | 16.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.78 | 13.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.03 | 10.5% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.66 | 6.5% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.24 | 6.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.21 | 6.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.92 | 5.8% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.28 | 5.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.34 | 3.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.18 | 3.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.06 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.25 | 3.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.07 | 3.3% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.54 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.49 | 1.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $21.17 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.71 | 1.4% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $19.77 | 1.4% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.55 | 1.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.59 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.77 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,436.18 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $242.57 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $162.17 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.24 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $88.21 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.92 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $76.28 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.14 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.68 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.68 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.73 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.34 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.18 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $39.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.53 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.61 | 2 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $19.77 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 670 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 124 |
| Lisinopril | Lisinopril | 301 | 103 |
| Montelukast Sodium | Montelukast Sodium | 295 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 94 |
| Gabapentin | Gabapentin | 277 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 88 |
| Losartan Potassium | Losartan Potassium | 235 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 69 |
| Furosemide | Furosemide | 194 | 74 |
| Omeprazole | Omeprazole | 188 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 55 |
| Ezetimibe | Ezetimibe | 173 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 70 |
| Jardiance | Empagliflozin | 166 | 47 |
| Trazodone Hcl | Trazodone Hcl | 159 | 45 |
| Ozempic | Semaglutide | 145 | 39 |
| Carvedilol | Carvedilol | 137 | 49 |
| Prednisone | Prednisone | 136 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 41 |
| Alprazolam | Alprazolam | 129 | 28 |
| Metformin Hcl | Metformin Hcl | 128 | 50 |
| Potassium Chloride | Potassium Chloride | 124 | 46 |
| Allopurinol | Allopurinol | 123 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 42 |
| Tramadol Hcl | Tramadol Hcl | 115 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 33 |
| Clonazepam | Clonazepam | 105 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 42 |
| Mounjaro | Tirzepatide | 101 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 89 | 22 |
| Pregabalin | Pregabalin | 88 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 83 | 57 |
| Bupropion Xl | Bupropion Hcl | 81 | 24 |
| Cephalexin | Cephalexin | 79 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 61 |
| Ramipril | Ramipril | 72 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 39 |
| Donepezil Hcl | Donepezil Hcl | 70 | 21 |
| Farxiga | Dapagliflozin Propanediol | 70 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 20 |
| Azithromycin | Azithromycin | 68 | 55 |
| Eliquis | Apixaban | 64 | 21 |
| Simvastatin | Simvastatin | 63 | 18 |
| Baclofen | Baclofen | 62 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 52 |
| Finasteride | Finasteride | 62 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 19 |
| Mupirocin | Mupirocin | 62 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 15 |
| Buspirone Hcl | Buspirone Hcl | 61 | 22 |
| Linzess | Linaclotide | 61 | 17 |
| Topiramate | Topiramate | 59 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 15 |
| Lorazepam | Lorazepam | 50 | 17 |
| Cefdinir | Cefdinir | 49 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 34 |
| Sertraline Hcl | Sertraline Hcl | 49 | 18 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 47 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | 12 |
| Mirtazapine | Mirtazapine | 46 | 16 |
| Famotidine | Famotidine | 45 | 20 |
| Spironolactone | Spironolactone | 45 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Anastrozole | Anastrozole | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | 14 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Synthroid | Levothyroxine Sodium | 39 | 13 |
| Valacyclovir | Valacyclovir Hcl | 39 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 11 |
| Sucralfate | Sucralfate | 38 | 18 |
| Dexamethasone | Dexamethasone | 37 | 28 |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 16 |
| Methocarbamol | Methocarbamol | 36 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 28 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 21 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Glyxambi | Empagliflozin/Linagliptin | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 11 |
| Valsartan | Valsartan | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 25 |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Indapamide | Indapamide | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 24 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Terconazole | Terconazole | 21 | 17 |
| Belsomra | Suvorexant | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 11 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clarithromycin | Clarithromycin | 17 | 13 |
| Estradiol | Estradiol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 14 |
| Nystatin | Nystatin | 17 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 12 |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Repaglinide | Repaglinide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,436.18 · 74 records | Corcept Therapeutics | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, ID NOW INSTRUMENT, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, INSPIRE, JARDIANCE, Kerendia, Korlym, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, RECORLEV, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error